CLDI — Calidi Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Calidi Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.9 | -25.4 | -29.2 | -22.2 | -20.1 |
| Depreciation | |||||
| Non-Cash Items | 1.4 | 8.38 | 8.08 | 3.81 | 1.86 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.61 | 3.57 | -6.24 | -1.7 | -4.74 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -7.77 | -13.2 | -27 | -19.7 | -21.3 |
| Capital Expenditures | -0.206 | -0.428 | -0.585 | -0.016 | -0.12 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.009 | -0.066 | 0.107 | — | -0.05 |
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.215 | -0.494 | -0.478 | -0.016 | -0.17 |
| Financing Cash Flow Items | 6.78 | 8.04 | 3.37 | 0.437 | -0.846 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.81 | 12.1 | 29 | 27.4 | 17.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.82 | -1.65 | 1.58 | 7.64 | -3.99 |